Read Larry Connors' blog – Short Term Trading Strategies
"As CalciMedica continues to execute on its business strategy and advance its lead drug program toward the clinic, Ev Graham's extensive experience in clinical development, corporate strategy and business development will be invaluable," said Gonul Velicelebi, Ph.D, Founder, President and Chief Executive Officer of CalciMedica. "Ev is an accomplished pharmaceutical executive and has earned wide respect in our industry for her diligence, integrity and strategic focus. We welcome Ev to CalciMedica's Board and look forward to working with her to shape our Company's future."
"It is an honor to join Gonul, the Board of Directors, and the CalciMedica team during this exciting period as the Company advances its first-in-class, small molecule immunomodulators toward key milestones," said Ms. Graham. "New mechanistic approaches that target the underlying causes of disease, such as CalciMedica's focus on selectively targeting CRAC channels, are critically needed. I believe that CalciMedica's novel drug discovery platform has significant potential to yield important new treatments for autoimmune and inflammatory diseases."
Evelyn Graham was formerly Chief Executive Officer and a director of TorreyPines Therapeutics, Inc., and led the company's merger with Raptor Pharmaceuticals Corp. in September 2009. Ms. Graham joined TorreyPines in 2004 as Vice President, Development; she became Vice President, Corporate Development in 2005 and Chief Operating Officer in 2006. Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, Ms. Graham was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in operations management, healthcare utilization, and organizational planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Ms. Graham holds a B.A. in biology from the University of Delaware and an M.B.A. from the University of Connecticut.
About CalciMedica, Inc.
CalciMedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. A significant focus of the company's drug discovery strategy is based on the specific inhibition of calcium release-activated calcium (CRAC) channels, a key component of the Icrac pathway in immune cells. The Icrac calcium entry pathway is essential for the adaptive immune response, and has been validated as an important drug target in humans. CalciMedica has acquired exclusive rights to STIM1 and Orai1 which function together as gatekeepers of the Icrac pathway and were cited in Science among signaling breakthroughs of 2005 and 2006, respectively. CalciMedica received its initial financing from SR One in December 2006 and closed its Series A in July 2007. The Series B financing was led by Sanderling Ventures, with participation from SR One, and closed in August 2007. The Series C round was led by Biogen Idec New Ventures, with participation from Sanderling Ventures and SR One, and closed in November 2008. CalciMedica is headquartered in La Jolla, California. For more information, please contact CalciMedica at info@calcimedica.com.
SOURCE CalciMedica, Inc.
http://www.calcimedica.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
